Research Article

Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle

Table 1

Efficacy outcomes of included trials.

Trial (first author, publication year)Interventions (only comparisons relevant to this meta-analysis listed)Randomised participants ( )   Timing of outcome assessment   PASI 75 [ (%)]PGA 0/1 [ (%)]

Etanercept trials

Papp et al., 2005 [9] Intervention:
Etanercept 50 mg BIW for 12 weeks, then 25 mg BIW for 12 weeks.203Week 24102 (50%)NA
Control intervention:
Placebo BIW for 12 weeks, then 25 mg BIW for 12 weeks.204Week 126 (3%)NA

Bagel et al., 2012 [19] Intervention:
Etanercept 50 mg BIW for 12 weeks, then 50 mg QW for 12 weeks.62Week 2443 (69%)39 (63%)
Control intervention:
Placebo BIW for 12 weeks, then 50 mg BIW for 12 weeks.62Week 123 (5%)3 (5%)

Adalimumab trials

Gordon et al., 2006 [10] Intervention:
Adalimumab 80 mg at week 0, then 40 mg EOW starting at week 1.46Week 2429 (63%)29 (63%)
Control intervention:
Placebo QW, then adalimumab 80 mg at week 12, followed by 40 mg EOW from week 13 on.52Week 122 (4%)NA

Menter et al., 2008 [12] Intervention:
Adalimumab 80 mg at week 0, then 40 mg EOW starting at week 1.814Week 24570 (70%)488 (60%)
Control intervention:
Placebo QW at week 0, then EOW beginning week 1 and through week 15, followed by 40 mg EOW from week 16 on.398Week 1626 (7%)16 (4%)

Asahina et al., 2010 [14] Intervention:
Adalimumab 80 mg at week 0, then 40 mg EOW starting at week 2.43Week 2430 (70%)25 (58%)
Control intervention:
Placebo EOW for 24 weeks.46Week 246 (13%)5 (11%)

Infliximab trials

Reich et al., 2005 [15] Intervention:
Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks.301Week 24227 (75.4%)203 (67.4%)
Control intervention:
Placebo at weeks 0, 2, and 6, then every 8 weeks.77Week 243 (3.8%)2 (2.6%)

Menter et al., 2007 [16] Intervention:
Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 week.150Week 26110 (73.3%)112 (74.6%)
Control intervention
Placebo at weeks 0, 2, and 6, switched to infliximab 5 mg/kg at week 16.208Week 104 (1.9%)2 (1%)

Torii and Nakagawa 2010 [17] Intervention:
Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks.35Week 2624 (68.6%)28 (80%)
Control intervention:
Placebo at weeks 0, 2, and 6, switched to infliximab 5 mg/kg at weeks 16.
19Week 100 (0%)2 (10.5%)

Ustekinumab trials

Leonardi et al., 2008 [11] Intervention:
(i) Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks.255Week 28178 (71%)147 (58%)
(ii) Ustekinumab 90 mg at weeks 0 and 4, then every 12 weeks.256Week 28191 (75%)161 (63%)
Control intervention:
Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks.255Week 128 (3%)10 (4%)

Papp et al., 2008 [13] Intervention:
(i) Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks.409Week 28276 (67%)243 (59%)
(ii) Ustekinumab 90 mg at weeks 0 and 4, then every 12 weeks.411Week 28314 (76%)280 (68%)
Control intervention:
Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks.410Week 1215 (4%)20 (5%)

Tsai et al., 2011 [18] Intervention:
Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks.61Week 2842 (69%)40 (66%)
Control intervention:
Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks.60Week 123 (5%)5 (8%)

Igarashi et al., 2012 [20] Intervention:
(i) Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks.65Week 2844 (68%)NA
(ii) Ustekinumab 90 mg at weeks 0 and 4, then every 12 weeks.62Week 2842 (68%)NA
Control intervention:
Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks.33Week 122 (6%)3 (9%)

Zheng et al., 2012 [21]Intervention:
Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks.160Week 28140 (88%)132 (83%)
Control intervention:
Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks.162Week 1218 (11%)24 (15%)

BIW: twice weekly; EOW: every other week, NA: not available; PASI 75: at least 75% reduction in the Psoriasis Area and Severity Index score; PGA 0/1: Physician’s Global Assessment clear or almost clear; QW: once weekly.